Abbott India has entered into strategic collaboration with Novo Nordisk India to commercialize Extensior for people living with type 2 diabetes. This partnership leverages Novo Nordisk’s scientific leadership in GLP-1s and Abbott’s strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves. Extensior is a second brand of Ozempic, the world’s most prescribed GLP-1 RA (receptor agonist) molecule.
Extensior is approved as an adjunct to diet and exercise for adults with type 2 diabetes and is a GLP-1 RA recognized for offering the broadest range of benefits for people with this condition. Semaglutide, the molecule in Extensior, has demonstrated powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes.
Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
